The battle between tumor suppressors: is gene therapy using p16(INK4a) more efficacious than p53 for treatment of ovarian carcinoma?
Murphy
M E
ME
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia Pennsylvania 19111, USA.
D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000628:therapy*; D019076:Transgenes
D019941:Cyclin-Dependent Kinase Inhibitor p16